CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids to create therapeutics for the treatment of inflammatory and metabolic diseases, today announced the initiation of a Phase 1 clinical trial for its lead product candidate CAT-1004. The compound, a novel conjugate of the essential omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate, is being developed to treat patients with type 2 diabetes. The current study will evaluate the safety, tolerability and pharmacokinetic profile of CAT-1004 in healthy adult subjects.
